Home » Topics » Regulatory » EMA

EMA
RSS

Lux Biosciences withdraws Luveniq MAA

Oct. 19, 2011

EMA confirms design of Intercell's planned phase II/III trial of Pseudomonas aeruginosa vaccine

Oct. 13, 2011

EMA recommends new orphan designation for 4SC-201

Oct. 13, 2011

EMA accepts MAA for IB-1001

Oct. 4, 2011

Aegerion gives update on European filing for lomitapide

Sep. 30, 2011

CHMP recommends approval of Prevanar 13 for new indication

Sep. 28, 2011

CHMP issues opinion on new indication for Avastin

Sep. 28, 2011

CHMP recommends approval of Alimta for new indication

Sep. 27, 2011

FDA approves new indication for Soliris

Sep. 27, 2011

Kombiglyze recommended for approval in E.U.

Sep. 27, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 13, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
LINC01116 has prognostic value in lung cancer, study shows
BioWorld MedTech
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...